This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) (pGGO)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2011 by Chen Weisheng, Dongfang Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Chen Weisheng, Dongfang Hospital Identifier:
First received: September 3, 2011
Last updated: September 6, 2011
Last verified: September 2011

With the advent of CT screening for lung cancer, there is an increase in the detection of pulmonary lesions with focal pure ground-glass opacity (pGGO). The pure Ground-glass opacities can be caused by normal expiration, partial filling of air spaces, partial collapse of alveoli, interstitial thickening, inflammation, oedema, fibrosis, and lepidic proliferation of neoplasm. Precise details of the natural history of focal pure GGO are still largely unclear. A number of differential diagnoses are possible, including inflammatory disease, focal scar, atypical adenomatous hyperplasia (AAH), and adenocarcinoma in situ. Some of pGGOs remained stable over a considerable time. A long doubling time for pGGOs is already known. Therefore, the strategy of treatment for focal pure GGO lesions is still undecided. The major issue is whether or not the doctors should treat these patients at all or wait until the first sign of a solid lesion developes which may take many years.

The purpose of this study is to determine if the ablation therapy is safe and effective for the pulmonary pGGO.

Condition Intervention Phase
Pulmonary Lesions Procedure: cryotherapy or radiofrequency ablation Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity

Resource links provided by NLM:

Further study details as provided by Chen Weisheng, Dongfang Hospital:

Primary Outcome Measures:
  • The changing of the lesion [ Time Frame: 3 years ]

    To determine the efficacy rate of CT image guided ablation for pulmonary focal pGGO.

    To determine the feasibility and safety of CT image guided ablation in patients with pulmonary pGGO.

Secondary Outcome Measures:
  • The side effect of the therapy. [ Time Frame: 3 years ]
    Intra and post-operative complications rates. Quality-of-life assessment

Estimated Enrollment: 100
Study Start Date: September 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ablation
Cryoablation or Radiofrequency ablation for the pGGO
Procedure: cryotherapy or radiofrequency ablation
Cryoablation or Radiofrequency ablation is performed under CT image guidance.
No Intervention: Follow up CT scann
The patients will receive follow up with CT scan every 6-9 months.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The lesion(s) treated with ablation must be =< 2.0 cm in greatest dimension
  • All patients are required to have been evaluated in a multi-disciplinary tumor conference to ensure that the lesion is suitable for Image-guided percutaneous ablation
  • Platelet count ≥ 100 x 109/L
  • International normalized ratio (INR) < 1.5
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
  • A signed study specific consent form is required

Exclusion Criteria:

  • Direct evidence of regional or distant metastases,or synchronous primary or prior malignancy in the past 5 years
  • Unable to lie flat or has respiratory distress at rest
  • Uncontrolled coagulopathy or bleeding disorders
  • Evidence of active systemic, pulmonary, or pericardial infection
  • Women who are pregnant or breastfeeding
  • Patients with poor pulmonary function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01429649

Contact: Weisheng Chen, MD +8618960826090

China, Fujian
Dongfang Hospital Recruiting
Fuzhou, Fujian, China, 350025
Contact: Yonggang Liang    +8659122859888 ext 59388   
Sponsors and Collaborators
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
Principal Investigator: Weisheng Chen, MD Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
  More Information

Responsible Party: Chen Weisheng, The vice chief of the Thoracic Division, Dongfang Hospital Identifier: NCT01429649     History of Changes
Other Study ID Numbers: kj2011001
Study First Received: September 3, 2011
Last Updated: September 6, 2011

Keywords provided by Chen Weisheng, Dongfang Hospital:
pure pulmonary ground glass opacity processed this record on September 20, 2017